New treatments for diabetes.
Mintz
Matthew L
ML
D058892:Adenosine Deaminase Inhibitors; D001645:Biguanides / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D018819:Dipeptidyl Peptidase 4; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004338:Drug Combinations; D006023:Glycoproteins / Q000037:antagonists & inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use
D058892:Adenosine Deaminase Inhibitors; D001645:Biguanides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004338:Drug Combinations; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D011719:Pyrazines; D013453:Sulfonylurea Compounds; D014230:Triazoles; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; D000068900:Sitagliptin Phosphate